Angela M Devlin

US Patent:

20040185487, Sep 23, 2004

Filed:

Mar 3, 2004

Appl. No.:

10/794282

Inventors:

Charles Halsted - Davis CA, US
Angela Devlin - Walnut Creek CA, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

International Classification:

C12Q001/00
C12Q001/68

US Classification:

435/006000

Abstract:

The invention provides methods for detecting mutations in the human GCPII gene which affect the ability of an individual to hydrolyze terminal glutamates from dietary folates. Such individuals are at increased risk for conditions associated with hyperhomocyteinemia, in particular, cardiovascular disease, colon cancer, and altered cognition in the elderly, including Alzheimer's disease. In addition, pregnant women with low folate status are at increased risk of bearing children with neural tube defects and congenital heart defects. Individuals with these mutations can be screened and treated with supplementation of their diet with folic acid.

US Patent:

20020009734, Jan 24, 2002

Filed:

Mar 12, 2001

Appl. No.:

09/805293

Inventors:

Charles Halsted - Davis CA, US
Angela Devlin - Walnut Creek CA, US

International Classification:

C12Q001/68
C12P019/34

US Classification:

435/006000, 435/091200

Abstract:

The invention provides methods for detecting mutations in the human GCPII gene which affect the ability of an individual to hydrolyze terminal glutamates from dietary folates. Such individuals are at increased risk for conditions associated with hyperhomocyteinemia, in particular, cardiovascular disease, colon cancer, and altered cognition in the elderly, including Alzheimer's disease. In addition, pregnant women with low folate status are at increased risk of bearing children with neural tube defects and congenital heart defects. Individuals with these mutations can be screened and treated with supplementation of their diet with folic acid.